Which has preferable earnings & valuation, OCS or ACOG?

Alpha Cognition has higher revenue and earnings than Oculis. Alpha Cognition is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 523.42 -$119.44M -$1.74 N/A Alpha Cognition $10.22M 20.78 -$20.67M -$1.10 N/A

Is OCS or ACOG more profitable?

Alpha Cognition has a net margin of -153.61% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Alpha Cognition's return on equity. Company Net Margins Return on Equity Return on Assets Oculis -6,777.18% -42.61% -35.23% Alpha Cognition -153.61% -54.60% -43.47%

Does the media refer more to OCS or ACOG?

In the previous week, Alpha Cognition had 18 more articles in the media than Oculis. MarketBeat recorded 19 mentions for Alpha Cognition and 1 mentions for Oculis. Alpha Cognition's average media sentiment score of 0.35 beat Oculis' score of -0.22 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GYRE or ACOG?

In the previous week, Alpha Cognition had 13 more articles in the media than Gyre Therapeutics. MarketBeat recorded 19 mentions for Alpha Cognition and 6 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.99 beat Alpha Cognition's score of 0.35 indicating that Gyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Cognition 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PHAT or ACOG?

In the previous week, Alpha Cognition had 17 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 19 mentions for Alpha Cognition and 2 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.19 beat Alpha Cognition's score of 0.35 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Cognition 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACOG or ACHV?

In the previous week, Alpha Cognition had 13 more articles in the media than Achieve Life Sciences. MarketBeat recorded 19 mentions for Alpha Cognition and 6 mentions for Achieve Life Sciences. Alpha Cognition's average media sentiment score of 0.35 beat Achieve Life Sciences' score of 0.28 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Achieve Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ZVRA or ACOG?

In the previous week, Alpha Cognition had 11 more articles in the media than Zevra Therapeutics. MarketBeat recorded 19 mentions for Alpha Cognition and 8 mentions for Zevra Therapeutics. Alpha Cognition's average media sentiment score of 0.35 beat Zevra Therapeutics' score of 0.32 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alpha Cognition (ACOG) Competitors

$9.75 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

ACOG vs. OCS, GYRE, PHAT, ACHV, and ZVRA

Should you buy Alpha Cognition stock or one of its competitors? Alpha Cognition's main competitors and comparable companies include Oculis (OCS), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Achieve Life Sciences (ACHV), and Zevra Therapeutics (ZVRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alpha Cognition compare to Oculis?

Oculis (NASDAQ:OCS) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Alpha Cognition had 18 more articles in the media than Oculis. MarketBeat recorded 19 mentions for Alpha Cognition and 1 mentions for Oculis. Alpha Cognition's average media sentiment score of 0.35 beat Oculis' score of -0.22 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oculis has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market.

Oculis currently has a consensus target price of $38.00, suggesting a potential upside of 190.30%. Alpha Cognition has a consensus target price of $18.00, suggesting a potential upside of 84.62%. Given Oculis' higher possible upside, research analysts plainly believe Oculis is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Alpha Cognition has a net margin of -153.61% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Alpha Cognition	-153.61%	-54.60%	-43.47%

22.3% of Oculis shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alpha Cognition has higher revenue and earnings than Oculis. Alpha Cognition is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	523.42	-$119.44M	-$1.74	N/A
Alpha Cognition	$10.22M	20.78	-$20.67M	-$1.10	N/A

Summary

Alpha Cognition beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Alpha Cognition compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Gyre Therapeutics has a net margin of -15.47% compared to Alpha Cognition's net margin of -153.61%. Gyre Therapeutics' return on equity of -6.57% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Alpha Cognition	-153.61%	-54.60%	-43.47%

Gyre Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Alpha Cognition. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.61	$5.03M	-$0.21	N/A
Alpha Cognition	$10.22M	20.78	-$20.67M	-$1.10	N/A

24.0% of Gyre Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 146.02%. Alpha Cognition has a consensus price target of $18.00, suggesting a potential upside of 84.62%. Given Gyre Therapeutics' higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Alpha Cognition had 13 more articles in the media than Gyre Therapeutics. MarketBeat recorded 19 mentions for Alpha Cognition and 6 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.99 beat Alpha Cognition's score of 0.35 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Gyre Therapeutics beats Alpha Cognition on 10 of the 16 factors compared between the two stocks.

How does Alpha Cognition compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Phathom Pharmaceuticals has a net margin of -41.34% compared to Alpha Cognition's net margin of -153.61%. Phathom Pharmaceuticals' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Alpha Cognition	-153.61%	-54.60%	-43.47%

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Phathom Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market.

Phathom Pharmaceuticals presently has a consensus target price of $22.86, indicating a potential upside of 157.69%. Alpha Cognition has a consensus target price of $18.00, indicating a potential upside of 84.62%. Given Phathom Pharmaceuticals' higher probable upside, equities research analysts clearly believe Phathom Pharmaceuticals is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Alpha Cognition has lower revenue, but higher earnings than Phathom Pharmaceuticals. Alpha Cognition is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.10	-$221.25M	-$1.28	N/A
Alpha Cognition	$10.22M	20.78	-$20.67M	-$1.10	N/A

In the previous week, Alpha Cognition had 17 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 19 mentions for Alpha Cognition and 2 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.19 beat Alpha Cognition's score of 0.35 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Phathom Pharmaceuticals beats Alpha Cognition on 11 of the 17 factors compared between the two stocks.

How does Alpha Cognition compare to Achieve Life Sciences?

Alpha Cognition (NASDAQ:ACOG) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Alpha Cognition has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -54.60% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Alpha Cognition has higher revenue and earnings than Achieve Life Sciences. Alpha Cognition is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	20.78	-$20.67M	-$1.10	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

Alpha Cognition presently has a consensus price target of $18.00, indicating a potential upside of 84.62%. Achieve Life Sciences has a consensus price target of $15.00, indicating a potential upside of 87.73%. Given Achieve Life Sciences' higher probable upside, analysts plainly believe Achieve Life Sciences is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Alpha Cognition had 13 more articles in the media than Achieve Life Sciences. MarketBeat recorded 19 mentions for Alpha Cognition and 6 mentions for Achieve Life Sciences. Alpha Cognition's average media sentiment score of 0.35 beat Achieve Life Sciences' score of 0.28 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Achieve Life Sciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

33.5% of Achieve Life Sciences shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Alpha Cognition beats Achieve Life Sciences on 9 of the 14 factors compared between the two stocks.

How does Alpha Cognition compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Alpha Cognition had 11 more articles in the media than Zevra Therapeutics. MarketBeat recorded 19 mentions for Alpha Cognition and 8 mentions for Zevra Therapeutics. Alpha Cognition's average media sentiment score of 0.35 beat Zevra Therapeutics' score of 0.32 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market.

Zevra Therapeutics presently has a consensus target price of $27.14, suggesting a potential upside of 128.67%. Alpha Cognition has a consensus target price of $18.00, suggesting a potential upside of 84.62%. Given Zevra Therapeutics' higher possible upside, research analysts plainly believe Zevra Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Zevra Therapeutics has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.62	$83.23M	$0.92	12.90
Alpha Cognition	$10.22M	20.78	-$20.67M	-$1.10	N/A

Zevra Therapeutics has a net margin of 42.82% compared to Alpha Cognition's net margin of -153.61%. Zevra Therapeutics' return on equity of 54.54% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Alpha Cognition	-153.61%	-54.60%	-43.47%

35.0% of Zevra Therapeutics shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by company insiders. Comparatively, 8.6% of Alpha Cognition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Zevra Therapeutics beats Alpha Cognition on 10 of the 16 factors compared between the two stocks.

Get Alpha Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACOG vs. The Competition

Export

Metric	Alpha Cognition	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$212.36M	$12.49B	$7.32B	$12.82B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	-8.86	789.80	272.91	24.33
Price / Sales	20.78	795.45	639.20	97.25
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	3.39	10.52	11.38	6.42
Net Income	-$20.67M	$2.81B	$3.47B	$348.89M
7 Day Performance	10.29%	2.49%	2.16%	0.51%
1 Month Performance	23.42%	5.06%	7.59%	4.84%
1 Year Performance	20.37%	7.26%	25.16%	17.04%

Alpha Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACOG Alpha Cognition	4.06 of 5 stars	$9.75 flat	$18.00 +84.6%	+20.4%	$212.36M	$10.22M	N/A	N/A	High Trading Volume
OCS Oculis	2.6336 of 5 stars	$12.89 +1.1%	$38.33 +197.4%	-26.7%	$747.36M	$1.45M	N/A	2
GYRE Gyre Therapeutics	2.6332 of 5 stars	$6.66 +0.3%	$17.00 +155.3%	-15.5%	$742.66M	$116.59M	N/A	40
PHAT Phathom Pharmaceuticals	3.3204 of 5 stars	$9.17 +7.8%	$23.43 +155.5%	-25.5%	$741.86M	$239.66M	N/A	110	Positive News
ACHV Achieve Life Sciences	2.934 of 5 stars	$6.69 -1.2%	$15.50 +131.7%	+173.6%	$686.79M	N/A	N/A	20	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACOG) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Cognition (ACOG) Competitors

ACOG vs. OCS, GYRE, PHAT, ACHV, and ZVRA

How does Alpha Cognition compare to Oculis?

Summary

How does Alpha Cognition compare to Gyre Therapeutics?

Summary

How does Alpha Cognition compare to Phathom Pharmaceuticals?

Summary

How does Alpha Cognition compare to Achieve Life Sciences?

Summary

How does Alpha Cognition compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Cognition (ACOG) Competitors

ACOG vs. OCS, GYRE, PHAT, ACHV, and ZVRA

How does Alpha Cognition compare to Oculis?

Does the media refer more to OCS or ACOG?

Which has more risk and volatility, OCS or ACOG?

Do analysts rate OCS or ACOG?

Is OCS or ACOG more profitable?

Do insiders & institutionals hold more shares of OCS or ACOG?

Which has preferable earnings & valuation, OCS or ACOG?

Summary

How does Alpha Cognition compare to Gyre Therapeutics?

Is GYRE or ACOG more profitable?

Which has more risk & volatility, GYRE or ACOG?

Which has higher earnings & valuation, GYRE or ACOG?

Do insiders and institutionals have more ownership in GYRE or ACOG?

Do analysts rate GYRE or ACOG?

Does the media refer more to GYRE or ACOG?

Summary

How does Alpha Cognition compare to Phathom Pharmaceuticals?

Is PHAT or ACOG more profitable?

Do institutionals and insiders believe in PHAT or ACOG?

Which has more risk & volatility, PHAT or ACOG?

Do analysts prefer PHAT or ACOG?

Which has better earnings and valuation, PHAT or ACOG?

Does the media prefer PHAT or ACOG?

Summary

How does Alpha Cognition compare to Achieve Life Sciences?

Which has more volatility & risk, ACOG or ACHV?

Is ACOG or ACHV more profitable?

Which has stronger earnings & valuation, ACOG or ACHV?

Do analysts prefer ACOG or ACHV?

Does the media prefer ACOG or ACHV?

Do institutionals and insiders have more ownership in ACOG or ACHV?

Summary

How does Alpha Cognition compare to Zevra Therapeutics?

Does the media refer more to ZVRA or ACOG?

Which has more volatility & risk, ZVRA or ACOG?

Do analysts prefer ZVRA or ACOG?

Which has better earnings & valuation, ZVRA or ACOG?

Is ZVRA or ACOG more profitable?

Do institutionals and insiders hold more shares of ZVRA or ACOG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools